Impact of increased uptake of long-acting injectable antiretroviral therapy on HIV incidence and viral suppression in the United States under 2021 FDA guidelines
CAB/RPV, even if only used among PWDH with VLS, may reduce HIV incidence and increase VLS, due to longer-lasting VLS postcessation of usage. If CAB/RPV also improves ART adherence, incidence is further reduced. Improved clinical efficacy of CAB/RPV may translate to improved population-level outcomes, even in limited use cases.
Authors
- Daniel Schreiber
- Katherine A. Hicks (ORCID: https://orcid.org/0000-0002-1058-3401)
- Justin Carrico (ORCID: https://orcid.org/0000-0002-4659-9309)
- Paul G. Farnham (ORCID: https://orcid.org/0000-0001-7815-5916)
- Jesse O’Shea (ORCID: https://orcid.org/0000-0001-7292-8834)
- Laurel Bates (ORCID: https://orcid.org/0000-0003-0142-4975)
- Joëlla W. Adams (ORCID: https://orcid.org/0000-0002-7703-5944)
- Alex Viguerie (ORCID: https://orcid.org/0000-0002-8556-3499)
- Cynthia M. Lyles (ORCID: https://orcid.org/0000-0002-4203-0414)
- Marie Johnston (ORCID: https://orcid.org/0000-0002-7308-1505)
Institutions
- Centers for Disease Control and Prevention (US)
- University of South Carolina (US)
- RTI International (US)
- University of Illinois Chicago (US)
- RTI Health Solutions (US)
- Aquarius Population Health (GB)
Publication Details
- Journal
- AIDS
- Published
- 2025-02-04
- DOI
- https://doi.org/10.1097/qad.0000000000004144
- Citations
- 2
- Primary Topic
- HIV/AIDS Research and Interventions
- Type
- article
- Field-Weighted Citation Impact
- 2.79